Skip To The Main Content

Another Perspective on rFC


I have noticed that a few articles have been published recently questioning the use of recombinant Factor C (rFC) assays to detect endotoxin contamination in parenterally administered pharmaceuticals or implanted medical devices [Editor’s Note: See list of previous rFC-related articles at end of article.]. There seems to be some confusion regarding the history of the development of the limulus amebocyte assay (LAL) assay, the development of the rFC assay and its regulatory status.

You need to Login to view the full article. Please Login. Not a Member? Join today!

PDA Members Save Substantially